SK 216

Key Product Details

Product Description

SK 216 is a plasminogen activator inhibitor-1 (PAI-1) inhibitor. Inhibits VEGF-induced migration and tube formation in HUVECs. Also attenuates TGF-β dependent epithelial-mesenchymal transition and fibroblast to myofibroblast differentiation in vitro. Reduces size and weight of subcutaneous tumors, and inhibits metastasis and angiogenesis in vivo. Reduces bleomycin-induced pulmonary fibrosis in vivo. Orally bioavailable.

Product Specifications for SK 216

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for SK 216

The following data is based on the product molecular weight 533.52.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.05 mM	37.49 mL	187.43 mL	374.87 mL
0.25 mM	7.50 mL	37.49 mL	74.97 mL
0.5 mM	3.75 mL	18.74 mL	37.49 mL
2.5 mM	0.75 mL	3.75 mL	7.50 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Takayama Inhibition of PAI-1 limits tumor angiogenesis regardless of angiogenic stimuli in malignant pleural mesothelioma. Cancer Res. 2016 PMID: 27197170
• Masuda SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis. Mol.Cancer Ther. 2013 PMID: 23990114
• Omori Inhibition of plasminogen activator inhibitor-1 attenuates transforming growth factor-β-dependent epithelial mesenchymal transition and differentiation of fibroblasts to myofibroblasts. PLoS One. 2016 PMID: 26859294

Product Documents for SK 216